Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Four-Drug cocktail shrink Hard-to-Treat lung tumors?

NCT ID NCT05258279

Completed Disease control Sponsor: Juntendo University Source: ClinicalTrials.gov ↗

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether adding lenvatinib to a standard chemotherapy-plus-immunotherapy regimen can shrink tumors in people with advanced non-squamous non-small cell lung cancer that has a specific EGFR mutation. Participants will receive lenvatinib capsules daily along with infusions of carboplatin, pemetrexed, and pembrolizumab every three weeks. The study aims to see how many patients respond to the combination and how safe it is.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a combination of lenvatinib, carboplatin, pemetrexed, and pembrolizumab
What this could lead to
If successful, this could offer a new treatment option for people with advanced EGFR-mutant lung cancer whose disease has progressed after standard therapy.
What could go wrong
This is a small, early-phase trial, so the combination may not prove more effective than existing treatments and could cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EGFR ACTIVATING MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EGFR ACTIVATING MUTATION NON-SQUAMOUS NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

  • Chiba University Hospital

    Chiba, Chiba, 26-8677, Japan

  • Juntendo University Hospital

    Bunkyo-ku, Tokyo, 113-8431, Japan

  • Juntendo Urayasu Hospital

    Urayasu, Chiba, 279-0021, Japan

  • Kanagawa Cancer Center

    Yokohama, Kanagawa, 241-8515, Japan

  • Kanagawa Cardiovascular and Respiratory Center

    Yokohama, Kanagawa, 236-0051, Japan

  • Saitama Cancer Center

    Shinden, Saitama, 362-0806, Japan

  • Saitama Medical University International Medical Center

    Hidaka, Saitama, 350-1298, Japan

  • Shizuoka Cancer Center

    Nagaizumi-cho, Shizuoka, 411-8777, Japan

  • St. Marianna University Hospital

    Kawasaki, Kanagawa, 216-8511, Japan

  • Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital

    Bunkyo-ku, Tokyo, 113-8677, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.